N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies.
about
Glycotherapy: new advances inspire a reemergence of glycans in medicineKey factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentGlycosylation of therapeutic proteins: an effective strategy to optimize efficacyAnalysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2007-2008.Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domainA Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives.Therapeutic antibodies: successes, limitations and hopes for the future.Bispecific antibodies for cancer therapy.Modulating antibody pharmacokinetics using hydrophilic polymers.Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.Bacterial protein N-glycosylation: new perspectives and applications.Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development.Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70).Clinical pharmacology of bispecific antibody constructs.Over-expression of a Codon Optimized Yeast Cytosolic Pyruvate Carboxylase (PYC2) in CHO Cells for an Augmented Lactate Metabolism.Half-life extended biotherapeutics.Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.Glycoengineering of CHO Cells to Improve Product Quality.Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.Metabolic engineering of CHO cells for the development of a robust protein production platform.Bioinformatics-led design of single-chain antibody molecules targeting DNA sequences for retinoblastoma.Cell culture media supplementation of infrequently used sugars for the targeted shifting of protein glycosylation profiles.Recombinant Proteins and Monoclonal Antibodies.ADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds
P2860
Q27027997-C2E995FE-BFE7-487F-8A4C-7606581747DAQ28082880-848A2403-BC4C-4B2F-B51F-36BEF04EEE70Q33586660-5BDC2279-E2CF-47C3-B824-D28B70FFEAEFQ33995843-04B0D927-A3C4-4CF6-8489-3511D99F303AQ34724092-D6A684B0-F664-4EF2-BB9B-B4A474BD848FQ35796700-F5EE0995-D087-4EBC-8C85-6919F36A6061Q35929084-A3F2D6FA-F78E-44FC-B31B-4F88AEC968ACQ36712597-B6BB34A6-79A8-4FD9-A459-3EEE3A70BE99Q36759405-340EA904-8D1C-4B7C-AE6F-8045A2A9B5F1Q37138252-0852DFD6-771E-41DE-9186-92C667222984Q37377633-44667A71-6543-4663-9C5D-AA8B04DDEDD4Q37491236-958DBB0F-27FC-45F6-9C34-D63034B0D40DQ37773263-93959E35-D457-47F2-BA2A-F4061D9EC7A7Q37919888-2506EA1B-4CDA-4A5B-9FD1-6A4AA318836AQ38074885-C1D473DC-D646-4934-A480-247E251971ADQ38074949-7F0CD89B-5FDA-49EC-9998-0F142920506CQ38236706-B4F4FF96-E7BF-4071-9716-7C1490C0A047Q38343221-F15DAEAA-1196-45DE-A885-F2C2600F70A7Q38364459-A1D2F043-D736-4382-A5EE-C23F289F647FQ38695847-C9B924D5-F73C-4D2C-9527-9E9A86C83A73Q38770067-537A2590-0CF3-40DC-B132-97CA17C7D264Q38834400-A4FDFC8A-9817-4C77-B475-4A9BAECF30C2Q39298073-89F9D4FB-F232-425C-B9B8-32ADCDB1062AQ41140868-D12D530C-06A8-49EF-A29C-CCD740DDEFF0Q41200443-7693ECCE-E822-40E2-B524-4BE345FDDB4DQ42044252-18669ADE-F8D0-47E9-826C-0001A1C6289BQ47598608-BF0649B2-FE36-4185-84ED-55BD291EC244Q47602370-614239FA-D182-4F52-AFAE-CEBCF486A03CQ58869554-5607F2B0-8D69-4B15-B5F2-2FB136BAE761
P2860
N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
N-glycosylation as novel strat ...... ecific single-chain diabodies.
@en
type
label
N-glycosylation as novel strat ...... ecific single-chain diabodies.
@en
prefLabel
N-glycosylation as novel strat ...... ecific single-chain diabodies.
@en
P2093
P2860
P356
P1476
N-glycosylation as novel strat ...... ecific single-chain diabodies.
@en
P2093
Dafne Müller
Franz-Georg Hanisch
Kirstin A Zettlitz
Miriam Rether
Roland E Kontermann
Roland Stork
P2860
P304
P356
10.1074/JBC.M709179200
P407
P577
2008-01-22T00:00:00Z